TransMedics Is Down 56% After 590 Days. What History Says

TransMedics Is Down 56% After 596 Days. What History Says

TransMedics Group, Inc. (TMDX) is down 56% from its all-time high as of June 24, 2026, having spent 596 days in this deep pullback. The Drawdown Severity Score™ has adjusted to 8.7, keeping the stock in the red zone after previously hitting deeper levels within that same zone. In the 3 comparable prior recoveries where the stock dropped by 50% or more, TMDX took an average of 472 days to recover.

Analyzing the Severity of the TMDX Drawdown

The current correction for TransMedics represents a significant departure from its historical trading patterns. With the stock trading at $77.61 as of June 24, 2026, it sits 55.9% below its peak of $176.11. This prolonged decline has lasted 596 days, indicating sustained downward pressure that has fundamentally altered the stock's medium-term trajectory.

Our proprietary Drawdown Severity Score™ ranks this event at an 8.7, which categorizes the correction as Very Large and places the asset deep within the red zone. The red zone represents the most severe tier of pullbacks, where price declines are driven by structural shifts in sentiment rather than normal market noise. For TMDX, staying in this zone for 596 days highlights the intensity of the current market cycle.

The Timeline and Historical Context

To put the current 596-day timeline into perspective, we must examine how TransMedics has behaved during previous market corrections. Historically, the company has experienced 41 total drawdown events since its public debut. The vast majority of these pullbacks were minor, short-lived events that resolved quickly.

The average maximum drawdown across all 41 historical events is -11.3%, with an average drawdown duration of just 46 days. The current decline of -55.9% lasting 596 days is an extreme statistical outlier. It has lasted more than twelve times longer than the historical average, demonstrating the unique nature of this market cycle.

Historical Drawdowns of 50% or More

While minor pullbacks are common, deep corrections are rare for this stock. Our database shows that TMDX has experienced a decline of 50% or more only 3 times in its history. This small sample size suggests that while severe drops occur, they are not a frequent feature of the stock's trading history.

In those 3 comparable historical drops, the average duration of the drawdown was 472 days. The current event has already persisted for 596 days, which means it has surpassed the historical average recovery time by 124 days. This extended duration indicates that the market is taking longer to digest the current headwinds than it did during previous deep corrections.

Because the historical data contains only 3 comparable events, investors should treat these averages with caution. Small sample sizes can skew historical benchmarks, as a single prolonged recovery can heavily impact the calculated average. However, the data confirms that the current 596-day correction is the longest period of price depression the stock has faced.

Valuation Context and Historical Multiples

To understand this price decline, we can examine the company's valuation multiples relative to its own history. As of 2026-06-24, the Price-to-Sales (P/S) ratio for TMDX is 4.2, which sits in the 2nd percentile of its own daily P/S record since 2019-05-02. This current multiple is historically low compared to its own past record, where the historical median P/S ratio is 16.2.

Peer Comparison and Sector Behavior

When high-growth medical technology stocks enter the red zone, their recovery paths often depend on broader sector trends. Many peers that experience a -55.9% peak decline face intense scrutiny regarding their operational metrics and capital allocation. Historically, companies in this zone require significant fundamental catalysts to transition from the red zone back into the orange or yellow zones.

Other stocks in the medical device and biotechnology sectors that have hit a severity score of 8.7 typically undergo a prolonged consolidation phase. During this phase, short-term trading volume often declines as speculative retail interest fades, leaving institutional accumulation to dictate the next leg of the recovery. For TMDX, stabilizing within the red zone suggests that the aggressive selling pressure may be pausing, even if a full trend reversal has not yet materialized.

News and Fundamental Catalysts

Several fundamental developments have influenced the stock's trajectory over the past year. According to PR Newswire, TransMedics reported its first quarter 2026 financial results, highlighting ongoing growth initiatives and expansion plans. However, a report by Quiver Quantitative noted that the stock fell following the first quarter 2026 earnings release, signaling that near-term performance failed to satisfy elevated market expectations.

Additionally, Yahoo Finance reported on the sharp one-year share price decline, which has forced analysts to re-evaluate the company's long-term valuation models. Legal developments have also added to the complexity: GlobeNewswire reported that Johnson Fistel is investigating TransMedics Group, Inc., introducing regulatory uncertainty that often weighs heavily on growth stocks. These combined factors explain why the stock has struggled to break out of its 596-day correction despite maintaining its underlying business expansion.

The Math of Recovery and Remaining Distance

The mathematical reality of deep drawdowns presents a steep hurdle for any asset trying to reclaim its peak. Because of the asymmetry of percentage losses and gains, a -55.9% decline requires a much larger percentage gain to break even. Specifically, TMDX must rise by 126.9% from its current price of $77.61 to reach its all-time high of $176.11.

This recovery process typically occurs in stages, marked by transitions through our proprietary severity zones. To move from the red zone (Very Large severity) into the orange zone (Large severity), the stock will need to establish a consistent series of higher lows. Investors tracking the asset will need to monitor whether the current stabilization can translate into sustained upward momentum, or if the stock will remain range-bound within the red zone.